vimarsana.com

Page 208 - ஒன்றுபட்டது மாநிலங்களில் பத்திரங்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Cell MedX Corp Converts Debt to Shares, Closes Non-Brokered Private Placement Financing, and Engages Investor Relations Consultants

(1) Carson City, Nevada (Newsfile Corp. - May 26, 2021) - Cell MedX Corp. (OTCQB: CMXC) ( Cell MedX or the Company ), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general health and wellness, is pleased to announce that on May 25, 2021, the Company issued 2,484,500 common shares of the Company (the Shares ) on conversion of $496,900 the Company owed its debt holders under 6% demand notes payable and non-interest-bearing advances. In addition to issuance of the shares, the Debt holders agreed to forgive $32,677 in accrued interest. Concurrently with conversion of debt, the Company closed a non-brokered private placement financing at a price of $0.20 per Share, by issuing 200,000 Shares for total gross proceeds of $40,000.

Green Globe International, Inc : Green Globe International (GGII) and Hempacco Announce Potential Consolidation

Green Globe International, Inc.: Green Globe International (GGII) and Hempacco Announce Potential Consolidation San Diego, California (Newsfile Corp. - May 26, 2021) - Hempacco Co., Inc. ( Hempacco ) and Green Globe International, Inc. (OTC PINK: GGII) ( Green Globe ) are pleased to announce that Green Globe and a majority of the shareholders of Hempacco have entered into a share exchange agreement pursuant to which Green Globe would acquire Hempacco in consideration of the issuance of 70,312,160,174 shares of common stock of Green Globe to Hempacco s shareholders. Shareholders representing 97.9757% of Hempacco s outstanding shares have signed the share exchange agreement, and Hempacco expects that the remaining Hempacco shareholders will sign the share exchange agreement in the coming days.

Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE®, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids

Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE®, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.